Hansa Biopharma AB, ("Hansa" or "the Company"), , today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imlifidase. The Company is ...
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types ...
The species Orcinus orca, generally known as orcas or killer whales, is made up of many genetically distinct populations ...
Lauren (Hansen) Holznienkemper is a lead editor for the small business vertical at Forbes Advisor, specializing in HR, payroll and recruiting solutions for small businesses. Using research and writing ...
Lund, Sweden, 16 December 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that GOOD-IDES-02, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Clay Halton was a Business Editor at Investopedia and has been working in the finance publishing field for more than five years. He also writes and edits personal finance content, with a focus on ...
ABSTRACT: Background: Streptococcus pyogenes or Groupe A Streptococcus (GAS) infections constitute a real public health problem due to their frequency and the post-infectious complications they cause.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback